Live Analyst Rating Changes 1844 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Rescott
BAIRD
David Rescott
Robert W. Baird
Wall Street Analyst
★★☆☆☆
#2006
on 13Foresight · ranked by our own returns
33%
Success Rate
-4.5%
Average Return
6 of 18 calls profitable · -92.3% vs benchmark
📈 Across the calls we could measure, roughly 33% of David Rescott's ratings turned a profit when each position was held for 1 year — averaging -4.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

49 Buy 25 Hold 0 Sell
David's Stock Coverage 18 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
MDT
Medtronic
 Jun 04, 2026 HOLD Buy
+23.6% avg upside
38 analysts
$85.00
6.96% Upside
 -3.2%
BSX
Boston Scientific
 May 28, 2026 BUY Strong Buy
+75.7% avg upside
38 analysts
$70.00
58.05% Upside
 -7.8%
HAE
Haemonetics
 May 08, 2026 BUY Strong Buy
-7.7% avg upside
17 analysts
$67.00
8.45% Downside
 +6.1%
LIVN
LivaNova
 May 07, 2026 BUY Strong Buy
+0.9% avg upside
14 analysts
$76.00
4.02% Downside
 -1.3%
TMDX
TransMedics Group
 May 06, 2026 BUY Strong Buy
+55.0% avg upside
15 analysts
$140.00
85.84% Upside
 +8.1%
INSP
Inspire Medical Systems
 May 05, 2026 HOLD Buy
+101.0% avg upside
20 analysts
$50.00
18.78% Upside
 -12.4%
MMSI
Merit Medical Systems
 May 01, 2026 BUY Strong Buy
+36.0% avg upside
15 analysts
$83.00
24.36% Upside
 +0.9%
RMD
Resmed
 May 01, 2026 HOLD Buy
+26.2% avg upside
27 analysts
$225.00
18.99% Upside
 -7.7%
IRTC
Irhythm Technologies
 May 01, 2026 BUY Strong Buy
+61.5% avg upside
19 analysts
$175.00
66.96% Upside
 ·
PRCT
PROCEPT BioRobotics
 Apr 30, 2026 HOLD Buy
+82.5% avg upside
16 analysts
$28.00
32.19% Upside
 -7.0%
EW
Edwards Lifesciences
 Apr 24, 2026 HOLD Strong Buy
+13.1% avg upside
34 analysts
$87.00
1.02% Upside
 +3.0%
ISRG
Intuitive Surgical
 Apr 22, 2026 BUY Strong Buy
+30.6% avg upside
36 analysts
$610.00
51.57% Upside
 -16.7%
NYXH
Nyxoah
 Mar 23, 2026 HOLD Strong Buy
+861.3% avg upside
12 analysts
$4.62
194.35% Upside
 -7.6%
PEN
Penumbra
 Jan 15, 2026 HOLD Buy
+4.7% avg upside
23 analysts
$374.00
18.22% Upside
 -9.8%
L
Loews
 Apr 24, 2025 HOLD Strong Buy
-55.4% avg upside
5 analysts
 — +28.5%
SIBN
SI-Bone
 Feb 28, 2023 BUY Strong Buy
+60.0% avg upside
18 analysts
$26.00
63.75% Upside
 -12.2%
ZBH
Zimmer Biomet Holdings
 Dec 21, 2021 BUY Buy
+28.1% avg upside
37 analysts
$145.00
64.58% Upside
 +7.8%
KIDS
OrthoPediatrics
 Dec 21, 2021 BUY Strong Buy
+62.5% avg upside
10 analysts
$75.00
305.24% Upside
 -34.2%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Rescott — Frequently Asked Questions
How accurate are David Rescott's stock ratings?
Based on the calls 13Foresight could measure, about 33% of David's ratings were profitable over a one-year hold, with an average return of -4.5% per rating, or -92.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Rescott is currently ranked #2006 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on MDT, BSX, HAE, LIVN, TMDX, INSP, MMSI, RMD, IRTC, PRCT, EW, ISRG and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.